B+
Bull case
20%
Probability
Target price
$15.00
Analysis reference price unavailable
Analysis 2026-08-14 · RankAlpha Sentiment Codex
OGN
OrganonBNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
55%
Probability
Target price
$14.00
Analysis reference price unavailable
Analysis 2026-08-14 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$11.50
Analysis reference price unavailable
Analysis 2026-08-14 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-14
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+63.0
Score
AI commentary
The post-earnings signal is mixed rather than clearly bullish: revenue modestly beat expectations, but adjusted EPS missed and margin compression weakened the operating read-through. The official filing confirms reduced disclosure during the merger, and no reliable post-print price reaction or analyst revision evidence is available. The result is a cautious monitoring view centered on merger completion and execution offsets, not a clean standalone re-rating.
RankAlpha Sentiment Codex - 2026-08-14
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-31eventMixed Q2 print leaves limited near-term upsideMedium impact
Stored AP/Zacks context reports Q2 revenue of $1.56 billion versus $1.54 billion consensus, but adjusted EPS of $0.85 versus $0.87 consensus. The official SEC filing confirms Organon furnished supplemental metrics instead of issuing a customary release or hosting an earnings call because of the pending Sun Pharma merger [#SEC-8K-2026-07-31]. [SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1821825/000110465926089008/tm2621744d1_8k.htm)
2026-11-30catalystMIUDELLA launch preparationMedium impact
Organon’s prior company update indicated that MIUDELLA, a hormone-free IUD, was anticipated to become commercially available in late 2026, providing a potential women’s-health offset as legacy contraception demand remains pressured [#IR-2026-06-22].
2026-12-31catalystBiosimilars must offset women’s-health erosionMedium impact
Q1 filing data showed Biosimilars revenue up 21% ex-FX while Women’s Health declined 19% ex-FX, with Nexplanon weakness a key pressure. Q2’s adjusted gross margin also fell to 58.7% from 61.7% year over year, so sustained biosimilar execution and cost control are needed for a stronger standalone thesis [#SEC-8K-2026-04-30] [#SEC-8K-2026-07-31]. [SEC Exhibit 99.1](https://www.sec.gov/Archives/edgar/data/1821825/000110465926089008/tm2621744d1_ex99-1.htm)
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-14 • Updated nightlySource: Internal modelMethodology